A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...